Identification

Name
Secobarbital
Accession Number
DB00418  (APRD00497)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal® and Tuinal) is a barbiturate derivative drug. It possesses anaesthetic, anticonvulsant, sedative and hypnotic properties. In the United Kingdom, it was known as Quinalbarbitone.

Structure
Thumb
Synonyms
  • (+-)-Secobarbital
  • (±)-secobarbital
  • 5-(1-Methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
  • 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
  • 5-allyl-5-(1-methylbutyl)barbituric acid
  • 5-Allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
  • Quinalbarbitone
  • Secobarbitalum
  • Secobarbitone
  • Seconal
Product Ingredients
IngredientUNIICASInChI Key
Secobarbital SodiumXBP604F6UM309-43-3AXXJTNXVUHVOJW-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Seconal Sodium Pulvule 240 0.1gmCapsule100 mgOralPharmascience Inc1939-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-secobarb 100mgCapsule100 mgOralNovopharm Limited1967-12-312005-08-10Canada
Seconal SodiumCapsule100 mg/1OralValeant Pharmaceuticals North America1983-10-03Not applicableUs
Seconal SodiumCapsule100 mg/1OralMarathon Pharmaceuticals1983-10-032016-09-30Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Tuinal Pulvule 303Secobarbital Sodium (50 mg) + Amobarbital sodium (50 mg)CapsuleOralPharmascience Inc1945-12-312004-03-05Canada
Tuinal Pulvule 304Secobarbital Sodium (100 mg) + Amobarbital sodium (100 mg)CapsuleOralPharmascience Inc1945-12-312004-03-05Canada
International/Other Brands
Seconal
Categories
UNII
1P7H87IN75
CAS number
76-73-3
Weight
Average: 238.2829
Monoisotopic: 238.131742452
Chemical Formula
C12H18N2O3
InChI Key
KQPKPCNLIDLUMF-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O

Pharmacology

Indication

For the Short-term treatment of intractable insomnia for patients habituated to barbiturates

Associated Conditions
Associated Therapies
Pharmacodynamics

Secobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

Mechanism of action

Secobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
UNMDA receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Secobarbital.Approved, Investigational
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Secobarbital.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Secobarbital.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Secobarbital.Approved
Acetyl sulfisoxazoleThe metabolism of Acetyl sulfisoxazole can be increased when combined with Secobarbital.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Secobarbital.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Adipiplon.Investigational
AgmatineThe metabolism of Agmatine can be increased when combined with Secobarbital.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alaproclate.Experimental
AldesleukinSecobarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfentanil.Approved, Illicit
AliskirenSecobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Allopregnanolone.Investigational
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Secobarbital.Approved, Investigational
AlosetronThe metabolism of Alosetron can be increased when combined with Secobarbital.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alphaprodine.Illicit
AlprazolamThe metabolism of Alprazolam can be increased when combined with Secobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Secobarbital.Experimental, Investigational
AmifostineSecobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideSecobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Secobarbital.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Secobarbital.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Secobarbital.Approved
AmiodaroneSecobarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Secobarbital.Approved
AmitriptylinoxideThe metabolism of Amitriptylinoxide can be increased when combined with Secobarbital.Approved, Investigational
AmlodipineSecobarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Secobarbital.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be increased when combined with Secobarbital.Approved
AmperozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amperozide.Experimental
Amphotericin BSecobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be increased when combined with Secobarbital.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Secobarbital.Approved
Amyl NitriteSecobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
AntipyrineThe metabolism of Antipyrine can be increased when combined with Secobarbital.Approved, Investigational
ApalutamideThe metabolism of Apalutamide can be increased when combined with Secobarbital.Approved, Investigational
ApixabanThe metabolism of Apixaban can be increased when combined with Secobarbital.Approved
ApomorphineSecobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineSecobarbital may increase the hypotensive activities of Apraclonidine.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Secobarbital.Experimental
AranidipineThe metabolism of Aranidipine can be increased when combined with Secobarbital.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be increased when combined with Secobarbital.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.Investigational
Arsenic trioxideSecobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be increased when combined with Secobarbital.Approved
ArticaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Asenapine.Approved
AsunaprevirThe metabolism of Asunaprevir can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Atazanavir can be increased when combined with Secobarbital.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Secobarbital.Approved
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Secobarbital.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Secobarbital.Approved, Vet Approved
AvatrombopagThe metabolism of Avatrombopag can be increased when combined with Secobarbital.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Azaperone.Investigational, Vet Approved
AzelastineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Secobarbital.Approved, Investigational
Azilsartan medoxomilSecobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzimilideThe metabolism of Azimilide can be increased when combined with Secobarbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.Illicit
BarnidipineSecobarbital may increase the hypotensive activities of Barnidipine.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Secobarbital.Experimental
BenazeprilSecobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Secobarbital.Experimental
BendroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Secobarbital.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Secobarbital.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzphetamine.Approved, Illicit
BenzthiazideSecobarbital may increase the orthostatic hypotensive activities of Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzyl alcohol.Approved
BepridilSecobarbital may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be increased when combined with Secobarbital.Investigational
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Secobarbital.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.Approved
BexaroteneThe metabolism of Bexarotene can be increased when combined with Secobarbital.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be increased when combined with Secobarbital.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Secobarbital.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.Approved
BortezomibThe metabolism of Bortezomib can be increased when combined with Secobarbital.Approved, Investigational
BosentanThe metabolism of Bosentan can be increased when combined with Secobarbital.Approved, Investigational
BretyliumSecobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brexpiprazole.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be increased when combined with Secobarbital.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
BrivaracetamThe metabolism of Brivaracetam can be increased when combined with Secobarbital.Approved, Investigational
BromazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromisoval.Experimental
BromocriptineSecobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Secobarbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Secobarbital.Experimental, Investigational
BumetanideSecobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bupivacaine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.Approved
BuprenorphineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineThe metabolism of Butriptyline can be increased when combined with Secobarbital.Approved
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.Approved
CabozantinibThe metabolism of Cabozantinib can be increased when combined with Secobarbital.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Secobarbital.Approved
CanagliflozinSecobarbital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanThe metabolism of Candesartan can be increased when combined with Secobarbital.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be increased when combined with Secobarbital.Approved
CanertinibThe risk or severity of adverse effects can be increased when Secobarbital is combined with Canertinib.Investigational
CannabidiolThe metabolism of Cannabidiol can be increased when combined with Secobarbital.Approved, Investigational
CaptoprilSecobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carbamazepine.Approved, Investigational
CarbetocinSecobarbital may increase the hypotensive activities of Carbetocin.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be increased when combined with Secobarbital.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Secobarbital.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Secobarbital.Experimental
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Secobarbital.Approved
CarvedilolSecobarbital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be increased when combined with Secobarbital.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Secobarbital.Approved, Investigational
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Secobarbital.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Secobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlordiazepoxide.Approved, Illicit, Investigational
ChlormadinoneThe therapeutic efficacy of Chlormadinone can be decreased when used in combination with Secobarbital.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
ChlorothiazideSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneSecobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorzoxazone.Approved
CilazaprilSecobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineSecobarbital may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Secobarbital.Approved, Investigational
CisaprideThe metabolism of Cisapride can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clemastine.Approved, Investigational
ClevidipineSecobarbital may increase the hypotensive activities of Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clobazam.Approved, Illicit
ClofarabineSecobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Secobarbital.Approved
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Secobarbital.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Secobarbital.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clothiapine.Experimental
ClozapineThe metabolism of Clozapine can be increased when combined with Secobarbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Secobarbital.Approved, Illicit
ConivaptanSecobarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
CyclandelateThe metabolism of Cyclandelate can be increased when combined with Secobarbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Secobarbital.Approved
CyclopenthiazideSecobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyproheptadine.Approved
Cyproterone acetateThe therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Secobarbital.Approved, Investigational
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Secobarbital.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.Approved, Investigational
DapagliflozinSecobarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be increased when combined with Secobarbital.Approved, Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Secobarbital.Experimental
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Secobarbital.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Secobarbital.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Secobarbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Secobarbital is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineThe metabolism of Dexniguldipine can be increased when combined with Secobarbital.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Secobarbital.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be increased when combined with Secobarbital.Experimental
DezocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dezocine.Approved, Investigational
DiazepamThe metabolism of Diazepam can be increased when combined with Secobarbital.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Secobarbital.Experimental
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Secobarbital.Approved, Vet Approved
DiclofenamideSecobarbital may increase the hypotensive activities of Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Secobarbital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Secobarbital.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diethyl ether.Experimental
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Secobarbital.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemSecobarbital may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.Approved
DimetacrineThe metabolism of Dimetacrine can be increased when combined with Secobarbital.Approved, Withdrawn
DinutuximabSecobarbital may increase the hypotensive activities of Dinutuximab.Approved, Investigational
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Secobarbital.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate.Approved, Illicit
DipyridamoleSecobarbital may increase the hypotensive activities of Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dixyrazine.Experimental
DoconexentThe metabolism of Doconexent can be increased when combined with Secobarbital.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be increased when combined with Secobarbital.Approved, Investigational
DomperidoneThe metabolism of Domperidone can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be increased when combined with Secobarbital.Approved
DopamineThe metabolism of Dopamine can be increased when combined with Secobarbital.Approved
DoramectinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Secobarbital.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Secobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Secobarbital.Investigational
DoxazosinSecobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Secobarbital.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Secobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Secobarbital is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Secobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Secobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.Approved, Investigational
EfonidipineSecobarbital may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be increased when combined with Secobarbital.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Eltanolone.Investigational
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Secobarbital.Approved
EmopamilThe metabolism of Emopamil can be increased when combined with Secobarbital.Experimental
EmpagliflozinSecobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilSecobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSecobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be increased when combined with Secobarbital.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.Approved
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Secobarbital.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Secobarbital.Approved, Investigational
EpitizideSecobarbital may increase the orthostatic hypotensive activities of Epitizide.Experimental
EplerenoneSecobarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Secobarbital.Approved
EprosartanSecobarbital may increase the hypotensive activities of Eprosartan.Approved
ErlotinibThe metabolism of Erlotinib can be increased when combined with Secobarbital.Approved, Investigational
EsatenololThe serum concentration of Esatenolol can be decreased when it is combined with Secobarbital.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be decreased when it is combined with Secobarbital.Approved
EstazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Estazolam.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Secobarbital.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be increased when combined with Secobarbital.Approved
EszopicloneThe metabolism of Eszopiclone can be increased when combined with Secobarbital.Approved, Investigational
Etacrynic acidSecobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
EthanolSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Secobarbital.Approved
EthosuximideThe metabolism of Ethosuximide can be increased when combined with Secobarbital.Approved
EthotoinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Secobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etizolam.Approved
EtodolacThe metabolism of Etodolac can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etomidate.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Secobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Secobarbital.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be increased when combined with Secobarbital.Approved
EzogabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ezogabine.Approved, Investigational
FelbamateThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.Approved
FelodipineSecobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Secobarbital.Withdrawn
FenoldopamSecobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fexofenadine.Approved, Investigational
FimasartanSecobarbital may increase the hypotensive activities of Fimasartan.Approved, Investigational
Fish oilThe metabolism of Fish oil can be increased when combined with Secobarbital.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Secobarbital.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be increased when combined with Secobarbital.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be increased when combined with Secobarbital.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Secobarbital.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Secobarbital.Approved, Investigational
FluspirileneThe metabolism of Fluspirilene can be increased when combined with Secobarbital.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Secobarbital.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be increased when combined with Secobarbital.Approved, Investigational
FosinoprilSecobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Fosphenytoin can be increased when combined with Secobarbital.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fospropofol.Approved, Illicit, Investigational
FurosemideSecobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe metabolism of Gabapentin can be increased when combined with Secobarbital.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin Enacarbil.Approved, Investigational
GallopamilThe metabolism of Gallopamil can be increased when combined with Secobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GanciclovirThe serum concentration of Ganciclovir can be decreased when it is combined with Secobarbital.Approved, Investigational
GavestinelThe metabolism of Gavestinel can be increased when combined with Secobarbital.Investigational
GepironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Secobarbital.Approved, Investigational
GestrinoneThe therapeutic efficacy of Gestrinone can be decreased when used in combination with Secobarbital.Approved
GliclazideThe metabolism of Gliclazide can be increased when combined with Secobarbital.Approved
GlimepirideThe metabolism of Glimepiride can be increased when combined with Secobarbital.Approved
GlipizideThe metabolism of Glipizide can be increased when combined with Secobarbital.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be increased when combined with Secobarbital.Approved
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Secobarbital.Approved, Investigational, Vet Approved
GuanfacineSecobarbital may increase the hypotensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be increased when combined with Secobarbital.Approved
HaloperidolThe metabolism of Haloperidol can be increased when combined with Secobarbital.Approved
HalothaneThe metabolism of Halothane can be increased when combined with Secobarbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Secobarbital.Approved
HydralazineSecobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be increased when combined with Secobarbital.Approved, Illicit
Hydroxyprogesterone caproateThe therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Secobarbital.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Secobarbital.Approved
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Secobarbital.Approved
IdarubicinThe metabolism of Idarubicin can be increased when combined with Secobarbital.Approved
IfosfamideThe metabolism of Ifosfamide can be increased when combined with Secobarbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.Approved
IloprostSecobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Imatinib can be increased when combined with Secobarbital.Approved
ImidaprilSecobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Secobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideSecobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Secobarbital.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indiplon.Investigational
IndisulamThe metabolism of Indisulam can be increased when combined with Secobarbital.Investigational
IndomethacinThe metabolism of Indomethacin can be increased when combined with Secobarbital.Approved, Investigational
IndoraminSecobarbital may increase the hypotensive activities of Indoramin.Withdrawn
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Secobarbital.Approved
IprindoleThe metabolism of Iprindole can be increased when combined with Secobarbital.Experimental
IrbesartanThe metabolism of Irbesartan can be increased when combined with Secobarbital.Approved, Investigational
IsocarboxazidSecobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineSecobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineSecobarbital may increase the hypotensive activities of Isradipine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be increased when combined with Secobarbital.Approved, Investigational
KetamineThe metabolism of Ketamine can be increased when combined with Secobarbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketazolam.Approved
KetobemidoneThe metabolism of Ketobemidone can be increased when combined with Secobarbital.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Secobarbital.Approved, Vet Approved
LabetalolSecobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineSecobarbital may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Secobarbital.Investigational
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Secobarbital.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be increased when combined with Secobarbital.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be increased when combined with Secobarbital.Approved, Investigational
LercanidipineSecobarbital may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be increased when combined with Secobarbital.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be increased when combined with Secobarbital.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be decreased when it is combined with Secobarbital.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be decreased when it is combined with Secobarbital.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocetirizine.Approved
LevodopaSecobarbital may increase the hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be increased when combined with Secobarbital.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Secobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol.Approved
LevosimendanSecobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be increased when combined with Secobarbital.Investigational
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Secobarbital.Experimental
LisinoprilSecobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Secobarbital.Experimental
LofexidineThe therapeutic efficacy of Secobarbital can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be increased when combined with Secobarbital.Experimental
LoperamideThe metabolism of Loperamide can be increased when combined with Secobarbital.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lormetazepam.Approved
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Secobarbital.Approved, Investigational
LosartanSecobarbital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.Approved
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Secobarbital.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.Approved, Investigational
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Secobarbital.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Secobarbital can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Secobarbital.Approved, Investigational
MannitolSecobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mebicar.Experimental
MecamylamineSecobarbital may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Medetomidine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be increased when combined with Secobarbital.Experimental, Investigational
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Secobarbital.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Secobarbital.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Secobarbital.Approved
Megestrol acetateThe therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Secobarbital.Approved, Investigational, Vet Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Secobarbital.Approved, Nutraceutical, Vet Approved
MelitracenThe metabolism of Melitracen can be increased when combined with Secobarbital.Experimental, Investigational
MeloxicamThe metabolism of Meloxicam can be increased when combined with Secobarbital.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Melperone.Approved, Investigational
MentholThe metabolism of Menthol can be increased when combined with Secobarbital.Approved
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Secobarbital.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Secobarbital.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.Approved, Investigational
MestranolThe metabolism of Mestranol can be increased when combined with Secobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.Approved
MethadoneThe metabolism of Methadone can be increased when combined with Secobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideSecobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methohexital.Approved
MethotrimeprazineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be increased when combined with Secobarbital.Approved
MethyclothiazideSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaSecobarbital may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylphenobarbital.Approved
MetipranololThe serum concentration of Metipranolol can be decreased when it is combined with Secobarbital.Approved
MetoclopramideThe therapeutic efficacy of Secobarbital can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneSecobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololSecobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Secobarbital.Approved
MetyrosineSecobarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Secobarbital.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Secobarbital is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Investigational
MinoxidilSecobarbital may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Moclobemide can be increased when combined with Secobarbital.Approved, Investigational
MoexiprilSecobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Molindone.Approved
MontelukastThe metabolism of Montelukast can be increased when combined with Secobarbital.Approved
MorphineThe metabolism of Morphine can be increased when combined with Secobarbital.Approved, Investigational
MoxonidineSecobarbital may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be increased when combined with Secobarbital.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be increased when combined with Secobarbital.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Secobarbital.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Secobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine.Approved
NaloxoneThe metabolism of Naloxone can be increased when combined with Secobarbital.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be increased when combined with Secobarbital.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be increased when combined with Secobarbital.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Secobarbital.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Neomycin.Approved, Vet Approved
NesiritideSecobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be increased when combined with Secobarbital.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be increased when combined with Secobarbital.Approved
NicardipineSecobarbital may increase the hypotensive activities of Nicardipine.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
NifedipineSecobarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Secobarbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Secobarbital.Experimental
NilvadipineSecobarbital may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
NimodipineSecobarbital may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineSecobarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrazepam.Approved
NitrendipineSecobarbital may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideSecobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinSecobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideSecobarbital may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidSecobarbital may increase the hypotensive activities of Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrous oxide.Approved, Vet Approved
Nomegestrol acetateThe therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Secobarbital.Approved, Investigational
NordazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nordazepam.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Secobarbital.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Norethisterone can be decreased when used in combination with Secobarbital.Approved
NorethynodrelThe therapeutic efficacy of Norethynodrel can be decreased when used in combination with Secobarbital.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Norflurane.Approved, Investigational
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Secobarbital.Approved, Investigational
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Secobarbital.Approved
NorgestrienoneThe therapeutic efficacy of Norgestrienone can be decreased when used in combination with Secobarbital.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Secobarbital.Approved
NylidrinThe metabolism of Nylidrin can be increased when combined with Secobarbital.Approved
ObinutuzumabSecobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be increased when combined with Secobarbital.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Secobarbital.Approved, Investigational
OlmesartanSecobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be increased when combined with Secobarbital.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Secobarbital.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ondansetron.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Secobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Opium.Approved, Illicit
OrphenadrineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be increased when combined with Secobarbital.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Secobarbital.Experimental, Investigational
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Secobarbital.Approved
OxazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.Approved
PapaverineSecobarbital may increase the hypotensive activities of Papaverine.Approved, Investigational
ParaldehydeSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Secobarbital.Approved
ParecoxibThe metabolism of Parecoxib can be increased when combined with Secobarbital.Approved
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Secobarbital.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be increased when combined with Secobarbital.Approved
PenbutololThe serum concentration of Penbutolol can be decreased when it is combined with Secobarbital.Approved, Investigational
PenfluridolThe metabolism of Penfluridol can be increased when combined with Secobarbital.Experimental
PentamidineThe metabolism of Pentamidine can be increased when combined with Secobarbital.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Secobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perazine.Approved, Investigational
PerindoprilSecobarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe metabolism of Perospirone can be increased when combined with Secobarbital.Approved
PerphenazineThe metabolism of Perphenazine can be increased when combined with Secobarbital.Approved
PethidineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be increased when combined with Secobarbital.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenazocine.Experimental
PhenelzineSecobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Secobarbital.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenoperidine.Experimental
PhenoxybenzamineSecobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Secobarbital.Approved, Investigational
PhentolamineSecobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Secobarbital.Approved, Vet Approved
PhenytoinThe metabolism of Phenytoin can be increased when combined with Secobarbital.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pimozide.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Secobarbital.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Secobarbital.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Secobarbital.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipamperone.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be increased when combined with Secobarbital.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Piritramide.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be increased when combined with Secobarbital.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Secobarbital.Approved
PizotifenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Secobarbital.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideSecobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be increased when combined with Secobarbital.Approved, Investigational
PractololThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.Approved
PramipexoleSecobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be increased when combined with Secobarbital.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Secobarbital.Approved
PrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam.Approved, Illicit
PrazosinSecobarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Secobarbital can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Secobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Secobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be increased when combined with Secobarbital.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be increased when combined with Secobarbital.Approved
PromazineThe metabolism of Promazine can be increased when combined with Secobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promethazine.Approved, Investigational
PropacetamolThe metabolism of Propacetamol can be increased when combined with Secobarbital.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Secobarbital.Approved
PropanididThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propoxycaine.Approved
PropranololSecobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Secobarbital.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Secobarbital is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pyrantel.Approved, Vet Approved
PyridoxineThe metabolism of Secobarbital can be increased when combined with Pyridoxine.Approved, Investigational, Nutraceutical, Vet Approved
QuazepamThe metabolism of Quazepam can be increased when combined with Secobarbital.Approved, Illicit
QuetiapineSecobarbital may increase the hypotensive activities of Quetiapine.Approved
QuinaprilSecobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneSecobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuingestanolThe therapeutic efficacy of Quingestanol can be decreased when used in combination with Secobarbital.Experimental
QuinidineThe metabolism of Quinidine can be increased when combined with Secobarbital.Approved, Investigational
QuinineThe metabolism of Quinine can be increased when combined with Secobarbital.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon.Approved, Investigational
RamiprilSecobarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineSecobarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be increased when combined with Secobarbital.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Secobarbital.Approved, Investigational
RifabutinThe metabolism of Secobarbital can be increased when combined with Rifabutin.Approved, Investigational
RifapentineThe metabolism of Secobarbital can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Secobarbital can be increased when combined with Rifaximin.Approved, Investigational
RiociguatThe metabolism of Riociguat can be increased when combined with Secobarbital.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Secobarbital.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Secobarbital is combined with Rizatriptan.Approved
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Romifidine.Vet Approved
RopiniroleSecobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Secobarbital.Approved, Investigational
RotigotineSecobarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Secobarbital.Approved
RupatadineThe metabolism of Rupatadine can be increased when combined with Secobarbital.Approved
SacubitrilSecobarbital may increase the hypotensive activities of Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.Approved, Investigational
SelegilineThe metabolism of Selegiline can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be increased when combined with Secobarbital.Investigational
SelexipagThe metabolism of Selexipag can be increased when combined with Secobarbital.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sepranolone.Investigational
SeratrodastThe metabolism of Seratrodast can be increased when combined with Secobarbital.Approved
SertindoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be increased when combined with Secobarbital.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be increased when combined with Secobarbital.Approved, Investigational
SimvastatinThe metabolism of Simvastatin can be increased when combined with Secobarbital.Approved
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Secobarbital.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be increased when combined with Secobarbital.Approved, Investigational
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Secobarbital.Approved
SpironolactoneSecobarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Stiripentol.Approved
StreptokinaseSecobarbital may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Secobarbital.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Secobarbital.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Secobarbital.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Secobarbital.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Secobarbital.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sumatriptan.Approved, Investigational
SuprofenThe metabolism of Suprofen can be increased when combined with Secobarbital.Approved, Withdrawn
SuvorexantSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Secobarbital.Investigational
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Secobarbital.Approved
TamsulosinSecobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tasimelteon.Approved, Investigational
TazaroteneThe metabolism of Tazarotene can be increased when combined with Secobarbital.Approved, Investigational
TelmisartanSecobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be increased when combined with Secobarbital.Approved, Investigational
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Secobarbital.Approved
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Secobarbital.Approved
TerazosinSecobarbital may increase the hypotensive activities of Terazosin.Approved
TerbutalineThe serum concentration of Terbutaline can be decreased when it is combined with Secobarbital.Approved
TerfenadineThe metabolism of Terfenadine can be increased when combined with Secobarbital.Approved, Withdrawn
TerodilineThe metabolism of Terodiline can be increased when combined with Secobarbital.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Secobarbital.Experimental
TestosteroneThe metabolism of Testosterone can be increased when combined with Secobarbital.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be increased when combined with Secobarbital.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be increased when combined with Secobarbital.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be increased when combined with Secobarbital.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be increased when combined with Secobarbital.Investigational
TetrandrineThe metabolism of Tetrandrine can be increased when combined with Secobarbital.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrodotoxin.Investigational
ThalidomideSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be increased when combined with Secobarbital.Approved
ThiamylalThe metabolism of Thiamylal can be increased when combined with Secobarbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiagabine.Approved, Investigational
TianeptineThe metabolism of Tianeptine can be increased when combined with Secobarbital.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be decreased when it is combined with Secobarbital.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Secobarbital.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tizanidine.Approved, Investigational
TolazolineSecobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Secobarbital.Approved, Investigational
TolcaponeSecobarbital may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be increased when combined with Secobarbital.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Topiramate.Approved
TorasemideThe metabolism of Torasemide can be increased when combined with Secobarbital.Approved
TrabectedinThe metabolism of Trabectedin can be increased when combined with Secobarbital.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.Approved, Investigational
TrandolaprilSecobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Secobarbital.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be increased when combined with Secobarbital.Approved, Investigational, Nutraceutical
TriamtereneSecobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.Approved, Vet Approved
TrimebutineThe metabolism of Trimebutine can be increased when combined with Secobarbital.Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Secobarbital.Approved
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Secobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Secobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Secobarbital.Investigational, Withdrawn
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Secobarbital.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Secobarbital.Approved
UlipristalThe therapeutic efficacy of Ulipristal can be decreased when used in combination with Secobarbital.Approved
ValaciclovirThe serum concentration of Valaciclovir can be decreased when it is combined with Secobarbital.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Secobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Valsartan can be increased when combined with Secobarbital.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vecuronium.Approved
VelpatasvirThe metabolism of Velpatasvir can be increased when combined with Secobarbital.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Veralipride.Experimental
VerapamilSecobarbital may increase the hypotensive activities of Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Secobarbital.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Secobarbital.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vinyl ether.Experimental
VismodegibThe metabolism of Vismodegib can be increased when combined with Secobarbital.Approved, Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Secobarbital.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be increased when combined with Secobarbital.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be increased when combined with Secobarbital.Approved, Investigational
WarfarinThe metabolism of Warfarin can be increased when combined with Secobarbital.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be increased when combined with Secobarbital.Experimental
XenonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Xenon.Experimental
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Secobarbital.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Secobarbital.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Secobarbital.Approved, Investigational
ZiconotideThe metabolism of Ziconotide can be increased when combined with Secobarbital.Approved
ZileutonThe metabolism of Zileuton can be increased when combined with Secobarbital.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolmitriptan.Approved, Investigational
ZolpidemSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe metabolism of Zonisamide can be increased when combined with Secobarbital.Approved, Investigational
ZopicloneThe metabolism of Zopiclone can be increased when combined with Secobarbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014562
KEGG Drug
D00430
PubChem Compound
5193
PubChem Substance
46508708
ChemSpider
5005
ChEBI
9073
ChEMBL
CHEMBL447
Therapeutic Targets Database
DAP000674
PharmGKB
PA164784035
Drugs.com
Drugs.com Drug Page
Wikipedia
Secobarbital
ATC Codes
N05CA06 — SecobarbitalN05CB01 — Combinations of barbiturates
AHFS Codes
  • 28:24.04 — Barbiturates
MSDS
Download (48.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Anabolic inc
  • Barr laboratories inc
  • Everylife
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Kv pharmaceutical co
  • Lannett co inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Purepac pharmaceutical co
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Wyeth ayerst laboratories
  • Ranbaxy pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Eli lilly and co
Packagers
  • Marathon Pharmaceuticals
  • Ohm Laboratories Inc.
  • Ranbaxy Laboratories
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral100 mg/1
CapsuleOral
Prices
Unit descriptionCostUnit
Seconal 100 mg capsule5.23USD capsule
Seconal sodium 100 mg capsule4.91USD capsule
Seconal sodium 100 mg pulvul0.93USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)100 °CPhysProp
water solubility550 mg/LNot Available
logP1.97HANSCH,C ET AL. (1995)
pKa7.8WOLLWEBER,H (1989)
Predicted Properties
PropertyValueSource
Water Solubility1.21 mg/mLALOGPS
logP2.2ALOGPS
logP2.03ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity62.65 m3·mol-1ChemAxon
Polarizability24.33 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9331
Blood Brain Barrier+0.9762
Caco-2 permeable-0.5792
P-glycoprotein substrateSubstrate0.6367
P-glycoprotein inhibitor INon-inhibitor0.5256
P-glycoprotein inhibitor IINon-inhibitor0.9756
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7863
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.736
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.7679
CYP450 2D6 inhibitorNon-inhibitor0.9276
CYP450 2C19 inhibitorNon-inhibitor0.7353
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9176
Ames testNon AMES toxic0.6131
CarcinogenicityNon-carcinogens0.8977
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity3.0894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9603
hERG inhibition (predictor II)Non-inhibitor0.9471
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.04 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0006-9400000000-7060c19b726fabf79a65
GC-MS Spectrum - CI-BGC-MSsplash10-000i-0090000000-cd7b7b08df2b25a36a42
Mass Spectrum (Electron Ionization)MSsplash10-014i-6900000000-eb3ae85faebb012ef83b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0190000000-db13804e78045568d611
1H NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:9073)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  5. Peters JA, Kirkness EF, Callachan H, Lambert JJ, Turner AJ: Modulation of the GABAA receptor by depressant barbiturates and pregnane steroids. Br J Pharmacol. 1988 Aug;94(4):1257-69. [PubMed:2850060]
  6. Miller LG, Deutsch SI, Greenblatt DJ, Paul SM, Shader RI: Acute barbiturate administration increases benzodiazepine receptor binding in vivo. Psychopharmacology (Berl). 1988;96(3):385-90. [PubMed:2906155]
  7. Kirkness EF, Turner AJ: The gamma-aminobutyrate/benzodiazepine receptor from pig brain. Purification and characterization of the receptor complex from cerebral cortex and cerebellum. Biochem J. 1986 Jan 1;233(1):265-70. [PubMed:3006661]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  9. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  10. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N: Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab Dispos. 1999 Mar;27(3):379-84. [PubMed:10064569]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cleveland clinic [Link]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:20